The preclinical findings described offer evidence that the combination of CTLA-4 blockade with various chemotherapeutic agents that exhibit different mechanisms of action, including ixabepilone, paclitaxel, etoposide, and gemcitabine, elicited synergistic antitumor activity in murine tumor models when administered concurrently. Here, CTLA4 is linked to neoplasm.